ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد ایتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Type, proportion, and duration of persistent COVID-19 symptoms*

Type, proportion, and duration of persistent COVID-19 symptoms*
Persistent symptom Proportion of patients
affected by symptom
Approximate time to symptom resolutionΔ
Common physical symptoms
Fatigue 15 to 87%[1,2,6,9,14,16] 3 months or longer
Dyspnea 10 to 71%[1,2,6-9,14] 2 to 3 months or longer
Chest discomfort 12 to 44%[1,2] 2 to 3 months
Cough 17 to 34%[1,2,9,12] 2 to 3 months or longer
Anosmia 10 to 13%[1,3-5,9,11] 1 month, rarely longer
Less common physical symptoms
Joint pain, headache, sicca syndrome, rhinitis, dysgeusia, poor appetite, dizziness, vertigo, myalgias, insomnia, alopecia, sweating, and diarrhea <10%[1,2,8,9,11] Unknown (likely weeks to months)
Psychologic and neurocognitive
Post-traumatic stress disorder 7 to 24%[6,10,14] 6 weeks to 3 months or longer
Impaired memory 18 to 21%[6,15] Weeks to months
Poor concentration 16%[6] Weeks to months
Anxiety/depression 22 to 23%[2,7,8,10,12-14] Weeks to months
Reduction in quality of life >50%[8] Unknown (likely weeks to months)

COVID-19: coronavirus disease 2019.

* These data are derived from an earlier period in the pandemic; information on patient recovery and persistent symptoms is evolving, and these figures may change as longer-term data emerge.

¶ More than a third of patients with COVID-19 experience more than one persistent symptom.

Δ Time course for recovery varies depending on premorbid risk factors and illness severity and may be shorter or longer than that listed. Hospitalized patients, and in particular critically ill patients, are more likely to have a more protracted course than those with mild disease.
References:
  1. Carfì A, Bernabei R, Landi F, et al. Persistent Symptoms in Patients After Acute COVID-19. JAMA 2020; 324:603.
  2. Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect 2020.
  3. Hopkins C, Surda P, Whitehead E, Kumar BN. Early recovery following new onset anosmia during the COVID-19 pandemic - an observational cohort study. J Otolaryngol Head Neck Surg 2020; 49:26.
  4. Cho RHW, To ZWH, Yeung ZWC, et al. COVID-19 Viral Load in the Severity of and Recovery From Olfactory and Gustatory Dysfunction. Laryngoscope 2020; 130:2680.
  5. Meini S, Suardi LR, Busoni M, et al. Olfactory and gustatory dysfunctions in 100 patients hospitalized for COVID-19: sex differences and recovery time in real-life. Eur Arch Otorhinolaryngol 2020; 277:3519.
  6. Halpin SJ, McIvor C, Whyatt G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol 2020.
  7. Bowles KH, McDonald M, Barrón Y, et al. Surviving COVID-19 After Hospital Discharge: Symptom, Functional, and Adverse Outcomes of Home Health Recipients. Ann Intern Med 2020.
  8. Wong AW, Shah AS, Johnston JC, et al. Patient-reported outcome measures after COVID-19: a prospective cohort study. Eur Respir J 2020; 56.
  9. Nehme M, Braillard O, Alcoba G, et al. COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings. Ann Intern Med 2020.
  10. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry 2020.
  11. Logue J K; Franko N M; McCulloch D J; et al. Sequelae in Adults at 6 Months After COVID-19 Infection JAMA Network Open. 2021;4(2):e210830.
  12. Mandal S, Barnett J, Brill S, et al. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax 2020; PMID 33172844.
  13. Bellan M, Soddu D, Balbo PE, et al. Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge. JAMA Netw Open. 2021;4(1):e2036142.
  14. Writing Committee for the COMEBAC Study Group, Morin L, Savale L, Pham T, et al. Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. JAMA. 2021; PMID 33729425.
  15. Del Brutto OH, Wu S, Mera A, Recalde et al. Cognitive decline among individuals with history of mild symptomatic SARS-CoV-2 infection: A longitudinal prospective study nested to a population cohort. Eur J Neurol 2021; PMID 33576150.
  16. Heesakkers H, van der Hoeven JG, Corsten S, et al. Clinical outcomes among patients with 1-year survival following intensive care unit treatment for COVID-19. JAMA 2022; PMID 35072716.
Graphic 130356 Version 5.0